These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

479 related articles for article (PubMed ID: 10612322)

  • 1. Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials.
    LaRosa JC; He J; Vupputuri S
    JAMA; 1999 Dec 22-29; 282(24):2340-6. PubMed ID: 10612322
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of statins in primary and secondary prevention of coronary heart disease and ischemic stroke. Meta-analysis of randomized trials.
    Vrecer M; Turk S; Drinovec J; Mrhar A
    Int J Clin Pharmacol Ther; 2003 Dec; 41(12):567-77. PubMed ID: 14692706
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pleiotropic effects of statins: benefit beyond cholesterol reduction? A meta-regression analysis.
    Robinson JG; Smith B; Maheshwari N; Schrott H
    J Am Coll Cardiol; 2005 Nov; 46(10):1855-62. PubMed ID: 16286171
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness of the addition of ezetimibe to ongoing statin therapy in modifying lipid profiles and attaining low-density lipoprotein cholesterol goals in older and elderly patients: subanalyses of data from a randomized, double-blind, placebo-controlled trial.
    Pearson T; Denke M; McBride P; Battisti WP; Brady WE; Palmisano J
    Am J Geriatr Pharmacother; 2005 Dec; 3(4):218-28. PubMed ID: 16503317
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low-Density Lipoprotein Cholesterol Lowering for the Primary Prevention of Cardiovascular Disease Among Men With Primary Elevations of Low-Density Lipoprotein Cholesterol Levels of 190 mg/dL or Above: Analyses From the WOSCOPS (West of Scotland Coronary Prevention Study) 5-Year Randomized Trial and 20-Year Observational Follow-Up.
    Vallejo-Vaz AJ; Robertson M; Catapano AL; Watts GF; Kastelein JJ; Packard CJ; Ford I; Ray KK
    Circulation; 2017 Nov; 136(20):1878-1891. PubMed ID: 28877913
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions: A Systematic Review and Meta-analysis.
    Silverman MG; Ference BA; Im K; Wiviott SD; Giugliano RP; Grundy SM; Braunwald E; Sabatine MS
    JAMA; 2016 Sep; 316(12):1289-97. PubMed ID: 27673306
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials.
    ; Mihaylova B; Emberson J; Blackwell L; Keech A; Simes J; Barnes EH; Voysey M; Gray A; Collins R; Baigent C
    Lancet; 2012 Aug; 380(9841):581-90. PubMed ID: 22607822
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT).
    ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial
    JAMA; 2002 Dec; 288(23):2998-3007. PubMed ID: 12479764
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Medical lipid-regulating therapy: current evidence, ongoing trials and future developments.
    Evans M; Roberts A; Davies S; Rees A
    Drugs; 2004; 64(11):1181-96. PubMed ID: 15161326
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness of statin therapy in adults with coronary heart disease.
    Wilt TJ; Bloomfield HE; MacDonald R; Nelson D; Rutks I; Ho M; Larsen G; McCall A; Pineros S; Sales A
    Arch Intern Med; 2004 Jul; 164(13):1427-36. PubMed ID: 15249352
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Efficacy and Safety of Evolocumab in High-Risk Patients Receiving a Statin: Secondary Analysis of Patients With Low LDL Cholesterol Levels and in Those Already Receiving a Maximal-Potency Statin in a Randomized Clinical Trial.
    Giugliano RP; Keech A; Murphy SA; Huber K; Tokgozoglu SL; Lewis BS; Ferreira J; Pineda AL; Somaratne R; Sever PS; Pedersen TR; Sabatine MS
    JAMA Cardiol; 2017 Dec; 2(12):1385-1391. PubMed ID: 29117276
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Statins in primary prevention of coronary heart disease].
    Paulweber B
    Wien Med Wochenschr; 1999; 149(5-6):129-38. PubMed ID: 10408004
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins.
    Baigent C; Keech A; Kearney PM; Blackwell L; Buck G; Pollicino C; Kirby A; Sourjina T; Peto R; Collins R; Simes R;
    Lancet; 2005 Oct; 366(9493):1267-78. PubMed ID: 16214597
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study.
    Downs JR; Clearfield M; Weis S; Whitney E; Shapiro DR; Beere PA; Langendorfer A; Stein EA; Kruyer W; Gotto AM
    JAMA; 1998 May; 279(20):1615-22. PubMed ID: 9613910
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An evidence-based assessment of the NCEP Adult Treatment Panel II guidelines. National Cholesterol Education Program.
    Ansell BJ; Watson KE; Fogelman AM
    JAMA; 1999 Dec; 282(21):2051-7. PubMed ID: 10591388
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Statin initiation following coronary artery bypass grafting: outcome of a hospital discharge protocol.
    Khanderia U; Townsend KA; Eagle K; Prager R
    Chest; 2005 Feb; 127(2):455-63. PubMed ID: 15705982
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials.
    Hebert PR; Gaziano JM; Chan KS; Hennekens CH
    JAMA; 1997 Jul 23-30; 278(4):313-21. PubMed ID: 9228438
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HDL-C: role as a risk modifier.
    Barter P
    Atheroscler Suppl; 2011 Nov; 12(3):267-70. PubMed ID: 22152280
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of modifying triglycerides and triglyceride-rich lipoproteins on cardiovascular outcomes.
    Abdel-Maksoud M; Sazonov V; Gutkin SW; Hokanson JE
    J Cardiovasc Pharmacol; 2008 Apr; 51(4):331-51. PubMed ID: 18427276
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 24.